Alnylam Pharmaceuticals reported $213.26M in Sales Revenues for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Sales Change
Acadia Pharmaceuticals ACAD:US $ 115.47M 15.29M
Alnylam Pharmaceuticals ALNY:US $ 213.26M 45.28M
Amgen AMGN:US $ 6238M 608M
Arrowhead Research ARWR:US $ 151.8M 124.37M
Biocryst Pharmaceuticals BCRX:US $ 49.92M 2.76M
Biomarin Pharmaceutical BMRN:US $ 519.36M 69.55M
Bluebird Bio BLUE:US $ 1.94M 0.34M
Intercept Pharmaceuticals ICPT:US $ 88.58M 3.82M
IONIS PHARMACEUT IONS:US $ 141.92M 298.09M
Mirati Therapeutics MRTX:US $ 0.71M 0.41M
Moderna Inc MRNA:US 6.07B 1.14B
Neurocrine Biosciences NBIX:US $ 310.6M 1.4M
Novartis NVS:US $ 12814M 708M
Ptc Therapeutics PTCT:US $ 148.74M 16.49M
Regeneron Pharmaceuticals REGN:US $ 2965.1M 1986.6M
Sangamo Biosciences SGMO:US $ 28.23M 0.24M
Sarepta Therapeutics SRPT:US $ 210.83M 9.37M
Takeda 4502:JP Y 873289M 28005M
Ultragenyx Pharmaceutical RARE:US $ 79.94M 3.45M
Vertex Pharmaceuticals VRTX:US $ 2097.5M 24.94M
Xencor XNCR:US $ 85.5M 68.52M
YTE INCY:US $ 733.24M 129.62M